OS | RFS | |||||
---|---|---|---|---|---|---|
P | HR | 95% CI | P | HR | 95% CI | |
Age | 0.099 | 1.524 | 0.924–2.512 | 0.622 | 1.123 | 0.708–1.781 |
Comorbidities | ||||||
CCI < 3 | 0.018 | 1.842 | 1.111–3.054 | 0.131 | 1.429 | 0.899–2.273 |
CCI ≥3 | ||||||
Grade | ||||||
Well/Moderate | 0.256 | 1.408 | 0.780–2.540 | 0.094 | 1.606 | 0.922–2.796 |
Poor | ||||||
Lymphovascular invasion | 0.844 | 1.058 | 0.603–1.856 | 0.121 | 1.528 | 0.894–2.613 |
Perineural invasion | 0.152 | 1.799 | 0.806–4.016 | 0.033 | 2.262 | 1.070–4.781 |
pT stage | ||||||
1–2 | 0.786 | 1.072 | 0.649–1.769 | 0.963 | 1.011 | 0.636–1.607 |
3–4 | ||||||
Lymph node involvement | 0.178 | 1.423 | 0.852–2.375 | 0.063 | 1.573 | 0.976–2.535 |
Pathologic stage | ||||||
I-II | 0.588 | 1.150 | 0.694–1.907 | 0.495 | 1.175 | 0.739–1.868 |
III-IV | ||||||
Resection margin | ||||||
Negative | 0.728 | 1.092 | 0.665–1.793 | 0.715 | 0.918 | 0.579–1.454 |
Positive | ||||||
Treatment | ||||||
Adjuvant CCRT | 0.224 | 1.378 | 0.822–2.309 | 0.016 | 1.802 | 1.118–2.904 |
Adjuvant chemotherapy |